A role for th2 cytokines in the suppression of CD8+ T cell-mediated graft rejection
- Ralph Scully,
- Stephen P. Cobbold,
- Andrew L. Mellor,
- Martin Wissing,
- Bernd Arnold,
- Herman Waldmann(corresponding author)
- Dana-Farber Cancer Institute,
- University of Oxford,
- Medical Research Council,
- Université libre de Bruxelles,
- German Cancer Research Center,
Abstract
A major histocompatibility complex (MHC) class I-specific T cell receptor (TCR)-transgenic mouse was used to study classical-type transplantation tolerance in the adult. Engraftment of MHC class I-incompatible bone marrow and tolerance to donor-type skin grafts were obtained using dimethylmyeleran (DMM) as a myeloabiative agent and a non-depleting anti-CD8 monoclonal antibody (mAb) as the sole immunosuppressant. Surprisingly, bone marrow engraftment was facilitated by host CD4+ T cells, a subset normally considered unable to reject class I MHC-incompatible grafts. A combination of mAb to interleukins (IL)-4 and -10 antagonized the 'permissive' effects of host CD4+ T cells, indicating a possible role for Th2-type immunoregulation that can act on CD8+ T cells in this form of transplantation tolerance. The fate of graft-reactive T cells was monitored using anti-clonotypic antibodies. It was observed that bone marrow engraftment then led to peripheral deletion of mAb-blockaded, clonotype+ CD8+ T cells.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 1663-1670 (8 pages)Journal (Volume, Issue Number)
European Journal of Immunology (Volume 27, Issue 7)Publication milestones
- Published - 07/1997
Publication status
ISSN
0014-2980Publication IDs
- Scopus: 0030750521
- PubMed: 9247575
